{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:58:48Z","timestamp":1782237528807,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lower urinary tract (LUT) dysfunctions affect millions of patients globally. LUT dysfunctions are extremely common in patients with neurological diseases. Worldwide, subtype A of Botulinum Toxin A (BTXA) is regularly used to treat these disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>LUT dysfunctions have various patterns of expression. The most prevalent of these is neurogenic detrusor overactivity (NDO), which is strongly associated with neurological diseases and can significantly impact a patient's life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Onabotulinumtoxin A is a widely used drug for the treatment of neurogenic bladder. The purpose of this study is to evaluate its efficacy and safety across different dosages in patients with the condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>Pubmed, Scopus, Web of Science.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Review Methods<\/jats:title>\n                    <jats:p>Systematic literature review was performed to identify randomized, double\u2010blind, placebo\u2010controlled trials of onabotulinumtoxin A for NDO. Seven randomized controlled trials were incorporated in this meta\u2010analysis. The primary outcome concerned urodynamic parameters, including Maximum Cystometric Capacity (MCC) and Maximum Detrusor Pressure (MDP); the mean number of Urinary Incontinence (UI) episodes per week was also assessed. Safety was evaluated by the incidence of various Adverse Events (AE). Data was extracted by two authors and statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS v.29).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven RCTs involving 1592 patients in total were included in the study, following screening of 1602 potentially relevant articles. The Onabotulinumtoxin A\u2014treated groups showed a significant increase in MCC (Mean Difference ([MD]: 128.866, 95% Confidence Interval [CI]: 98.836, 158.896,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, in the group that received 200 Units of Onabotulinumtoxin A; MD: 151.389, CI: 106.006, 196.773,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.005, in the group that received 300Units of Onabotulinumtoxin A). There was also a significant decrease in MDP in the Onabotulinumtoxin A\u2010treated groups (MD: \u221229.051, CI: \u221239.557, \u221218.545,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.002, 200\u2009U group; MD: \u221231.751, CI: \u221245.226, \u221218.276,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01, 300\u2009U group). Additionally, no effect was noticed in the mean number of UI episodes per week (MD: \u221210.69, 95% CI: \u221233.86, 12.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.11; MD: \u221210.55, 95% CI: \u221259.06, 37.97,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.22, 200\u2009U and 300\u2009U respectively). Taking AEs into consideration, Onabotulinumtoxin A\u2010treated groups were often associated with more complications, including urinary tract infections (UTI) (LogOR: 0.341, CI: 0.011, 0.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045, 200\u2009U group; LogOR: 0.424, CI: 0.075, 0.773,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028, 300\u2009U group) and urinary retention (UR) (LogOR: 1.746, CI: 0.869, 2.623,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008, 200\u2009U group; LogOR: 1.879, CI: 0.679, 3.078,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021, 300\u2009U group).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our meta\u2010analyses found that Onabotulinumtoxin A can be beneficial in improving the urodynamic parameters (MCC and MDP). As far as safety is concerned, the drug\u2010treated groups had a slightly higher likelihood of developing UTI or UR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.70211","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:29:22Z","timestamp":1768379362000},"page":"335-352","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness of Botulinum Toxin a Versus Placebo for Neurogenic Overactive Bladder: A Meta\u2010Analysis"],"prefix":"10.1002","volume":"45","author":[{"given":"Konstantinos","family":"Tassoudis","sequence":"first","affiliation":[{"name":"University Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachos","family":"Ioannis","sequence":"additional","affiliation":[{"name":"University Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitropoulos","family":"Konstatninos","sequence":"additional","affiliation":[{"name":"University Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evmorfopoulos","family":"Konstantinos","sequence":"additional","affiliation":[{"name":"University Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsitopoulos","family":"Konstantinos","sequence":"additional","affiliation":[{"name":"University Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Tassoudis","sequence":"additional","affiliation":[{"name":"University Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Tzortzis","sequence":"additional","affiliation":[{"name":"University Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11884-020-00622-z"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353274"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1713876"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.5535\/arm.2014.38.3.347"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1755738019874839"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21003"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2015.1065792"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-010-1720-x"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","unstructured":"The Origin Structure and Pharmacological Activity of Botulinum Toxin. | Pharmacological Reviews accessed November 6 2024 https:\/\/pharmrev.aspetjournals.org\/content\/33\/3\/155.long.","DOI":"10.1016\/S0031-6997(25)06852-8"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2011.110"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"e_1_2_13_13_1","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions accessed November 4 2024 https:\/\/training.cochrane.org\/handbook\/current."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/83.8.713"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjpt.2019.11.002"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.02.004"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22376"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0984-0"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14602"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2012.03218.x"},{"key":"e_1_2_13_24_1","unstructured":"EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction \u2013 PubMed accessed November 8 2024 https:\/\/pubmed.ncbi.nlm.nih.gov\/19403235\/."},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.009"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2010.06.001"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000054774"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127725.48479.89"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.010"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.005"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.013"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.08.052"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101736"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.70211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:37:00Z","timestamp":1770817020000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/nau.70211"],"URL":"https:\/\/doi.org\/10.1002\/nau.70211","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"2025-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}